Search Press releases Keywords From To 26 Jun 2023 UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab Read More 26 Jun 2023 Change in UCB’s Executive Committee Read More 20 Jun 2023 UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress Read More 7 Jun 2023 UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis Read More 31 May 2023 New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023 Read More 30 May 2023 UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023 Read More Pagination First page Previous page Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
